Journal of Otolaryngology and Ophthalmology of Shandong University ›› 2023, Vol. 37 ›› Issue (1): 145-151.doi: 10.6040/j.issn.1673-3770.0.2021.468

Previous Articles    

Progress in the applications of XEN microstent in glaucoma surgery

ZHONG Yu1, LIAO Zhimin1, DUAN Xuanchu2   

  1. 1. Department of Ophthalmology, Aier School of Ophthalmology, Central South University/ Changsha Aier Eye Hospital/ Aier Eye Hospital of Wuhan University, Wuhan 430061, Hubei, China;
    2. Department of Ophthalmology, Aier School of Ophthalmology, Central South University/ Changsha Aier Eye Hospital, Changsha 410015, Hunan, China
  • Published:2023-02-06

PDF (PC)

197

Abstract: The major target of glaucoma treatment is lowing intraocular pressure, to prevent further optic nerve damage. The limit of traditional procedures, like the unstable postoperative intraocular pressure and postoperative complications, has contributed to the emergence of a new type of minimally anvasive glaucoma surgery, such as the XEN microstent implantation. The effectiveness and safety of this new technology have been confirmed in many clinical studies and have thus been gaining more attention. To enable ophthalmologists to better understand XEN microstent implantation in glaucoma surgery, this paper summarizes the applications and research progress of XEN microstent implantation in glaucoma surgery by analyzing and summarizing the related literatures on XEN microstent implantation in recent years.

Key words: Glaucoma, XEN microstents, Minimally invasive glaucoma surgery

CLC Number: 

  • R775
[1] Chaudhary A, Salinas L, Guidotti J, et al. XEN Gel Implant: a new surgical approach in glaucoma[J]. Expert Rev Med Devices, 2018, 15(1): 47-59. doi:10.1080/17434440.2018.1419060
[2] Fea AM, Durr GM, Marolo P, et al. XEN® gel stent: a comprehensive review o2 its use as a treatment option for refractory glaucoma[J]. Clin Ophthalmol, 2020, 14: 1805-1832. doi:10.2147/OPTH.S178348
[3] Lewis RA. Ab interno approach to the subconjunctival space using a collagen glaucoma stent[J]. J Cataract Refract Surg, 2014, 40(8): 1301-1306. doi:10.1016/j.jcrs.2014.01.032
[4] Kerr NM, Wang J, Barton K. Minimally invasive glaucoma surgery as primary stand-alone surgery for glaucoma[J]. Clin Exp Ophthalmol, 2017, 45(4): 393-400. doi:10.1111/ceo.12888
[5] Sheybani A, Lenzhofer M, Hohensinn M, et al. Phacoemulsification combined with a new ab interno gel stent to treat open-angle glaucoma: pilot study[J]. J Cataract Refract Surg, 2015, 41(9): 1905-1909. doi:10.1016/j.jcrs.2015.01.019
[6] Sheybani A, Reitsamer H, Ahmed II. Fluid dynamics of a novel micro-fistula implant for the surgical treatment of glaucoma[J]. Invest Ophthalmol Vis Sci, 2015, 56(8): 4789-4795. doi:10.1167/iovs.15-16625
[7] Lavin-Dapena C, Cordero-Ros R, D'Anna O, et al. XEN 63 gel stent device in glaucoma surgery: a 5-years follow-up prospective study[J]. Eur J Ophthalmol, 2021, 31(4): 1829-1835. doi:10.1177/1120672120952033
[8] Sheybani A, Dick HB, Ahmed II. Early clinical results of a novel ab interno gel stent for the surgical treatment of open-angle glaucoma[J]. J Glaucoma, 2016, 25(7): e691-e696. doi:10.1097/IJG.0000000000000352
[9] Reitsamer H, Sng C, Vera V, et al. Two-year results of a multicenter study of the ab interno gelatin implant in medically uncontrolled primary open-angle glaucoma[J]. Albrecht Von Graefes Arch Fur Klinische Und Exp Ophthalmol, 2019, 257(5): 983-996. doi:10.1007/s00417-019-04251-z
[10] Ucar F, Cetinkaya S. Xen implantation in patients with primary open-angle glaucoma: comparison of two different techniques[J]. Int Ophthalmol, 2020, 40(10): 2487-2494. doi:10.1007/s10792-020-01427-z
[11] Kalina AG, Kalina PH, Brown MM. XEN® gel stent in medically refractory open-angle glaucoma: results and observations after one year of use in the United States[J]. Ophthalmol Ther, 2019, 8(3): 435-446. doi:10.1007/s40123-019-0192-8
[12] Mansouri K, Bravetti GE, Gillmann K, et al. Two-year outcomes of XEN gel stent surgery in patients with open-angle glaucoma[J]. Ophthalmol Glaucoma, 2019, 2(5): 309-318. doi:10.1016/j.ogla.2019.03.011
[13] Marcos Parra MT, Salinas López JA, López Grau NS, et al. XEN implant device versus trabeculectomy, either alone or in combination with phacoemulsification, in open-angle glaucoma patients[J]. Albrecht Von Graefes Arch Fur Klinische Und Exp Ophthalmol, 2019, 257(8): 1741-1750. doi:10.1007/s00417-019-04341-y
[14] Fernández-García A, Zhou Y, García-Alonso M, et al. Medium-term clinical outcomes following Xen45 device implantation[J]. Int Ophthalmol, 2020, 40(3): 709-715. doi:10.1007/s10792-019-01232-3
[15] Olgun A, Aktas Z, Ucgul AY. XEN gel implant versus gonioscopy-assisted transluminal trabeculotomy for the treatment of open-angle glaucoma[J]. Int Ophthalmol, 2020, 40(5): 1085-1093. doi:10.1007/s10792-019-01271-w
[16] Ibáñez-Muñoz A, Soto-Biforcos VS, Chacón-González M, et al. One-year follow-up of the XEN® implant with mitomycin-C in pseudoexfoliative glaucoma patients[J]. Eur J Ophthalmol, 2019, 29(3): 309-314. doi:10.1177/1120672118795063
[17] Mansouri K, Gillmann K, Rao HL, et al. Prospective evaluation of XEN gel implant in eyes with pseudoexfoliative glaucoma[J]. J Glaucoma, 2018, 27(10): 869-873. doi:10.1097/IJG.0000000000001045
[18] Gillmann K, Bravetti GE, Mermoud A, et al. XEN gel stent in pseudoexfoliative glaucoma: 2-year results of a prospective evaluation[J]. J Glaucoma, 2019, 28(8): 676-684. doi:10.1097/IJG.0000000000001295
[19] Hohberger B, Welge-Lüβen UC, Lämmer R. MIGS: therapeutic success of combined Xen Gel Stent implantation with cataract surgery[J]. Albrecht Von Graefes Arch Fur Klinische Und Exp Ophthalmol, 2018, 256(3): 621-625. doi:10.1007/s00417-017-3895-3
[20] Ba??塂er EF, Seymenoglu RG. Results of fluorouracil-augmented Xen45 implantation in primary open-angle and pseudoexfoliation glaucoma[J]. Int Ophthalmol, 2021, 41(3): 945-955. doi:10.1007/s10792-020-01650-8
[21] Klug E, Solá-Del Valle D. Bilateral XEN gel stent implantation in juvenile-onset open-angle glaucoma[J]. Case Rep Ophthalmol, 2020, 11(2): 336-341. doi:10.1159/000508391
[22] Schlenker MB, Gulamhusein H, Conrad-Hengerer I, et al. Efficacy, safety, and risk factors for failure of standalone ab interno gelatin microstent implantation versus standalone trabeculectomy[J]. Ophthalmology, 2017, 124(11): 1579-1588. doi:10.1016/j.ophtha.2017.05.004
[23] Widder RA, Dietlein TS, Dinslage S, et al. The XEN45 Gel Stent as a minimally invasive procedure in glaucoma surgery: success rates, risk profile, and rates of re-surgery after 261 surgeries[J]. Albrecht Von Graefes Arch Fur Klinische Und Exp Ophthalmol, 2018, 256(4): 765-771. doi:10.1007/s00417-018-3899-7
[24] Morgan WH, Yu DY. XEN-45 gelatin microfistula for uveitic glaucoma[J]. Clin Exp Ophthalmol, 2018, 46(4): 323-324. doi:10.1111/ceo.13307
[25] Sng CC, Wang J, Hau S, et al. XEN-45 collagen implant for the treatment of uveitic glaucoma[J]. Clin Exp Ophthalmol, 2018, 46(4): 339-345. doi:10.1111/ceo.13087
[26] Yu JTS, Au L. Conjunctival bleb compression as a treatment for hypotony post XEN45 implant in uveitic glaucoma[J]. Eur J Ophthalmol, 2020, 30(1): 217-220. doi:10.1177/1120672119836339
[27] Widder RA, Lappas A, Rennings C, et al. Primary versus posttrabeculectomy XEN45 gel stent implantation: comparison of success rates and intraocular pressure-lowering potential in pseudophakic eyes[J]. J Glaucoma, 2020, 29(12): 1115-1119. doi:10.1097/IJG.0000000000001649
[28] Lindland A, Edward Michelet JT, Slagsvold JE. Use of the XEN gel implant in a patient with aniridia-associated glaucoma[J]. Am J Ophthalmol Case Rep, 2021, 22: 101080. doi:10.1016/j.ajoc.2021.101080
[29] De Gregorio A, Pedrotti E, Stevan G, et al. XEN glaucoma treatment system in the management of refractory glaucomas: a short review on trial data and potential role in clinical practice[J]. Clin Ophthalmol, 2018, 12: 773-782. doi:10.2147/OPTH.S146919
[30] Ozal SA, Kaplaner O, Basar BB, et al. An innovation in glaucoma surgery: XEN45 gel stent implantation[J]. Arq Bras Oftalmol, 2017, 80(6): 382-385. doi:10.5935/0004-2749.20170093
[31] Galal A, Bilgic A, EltanamLy R, et al. XEN glaucoma implant with mitomycin C1-year follow-up: result and complications[J]. J Ophthalmol, 2017, 2017: 5457246. doi:10.1155/2017/5457246
[32] de Gregorio A, Pedrotti E, Russo L, et al. Minimally invasive combined glaucoma and cataract surgery: clinical results of the smallest ab interno gel stent[J]. Int Ophthalmol, 2018, 38(3): 1129-1134. doi:10.1007/s10792-017-0571-x
[33] Mansouri K, Guidotti J, Rao HL, et al. Prospective evaluation of standalone XEN gel implant and combined phacoemulsification-XEN gel implant surgery: 1-year results[J]. J Glaucoma, 2018, 27(2): 140-147. doi:10.1097/IJG.0000000000000858
[34] Poelman HJ, Pals J, Rostamzad P, et al. Efficacy of the XEN-implant in glaucoma and a meta-analysis of the literature[J]. J Clin Med, 2021, 10(5): 1118. doi:10.3390/jcm10051118
[35] Roberts DK, Newman TL, Roberts MF, et al. Long anterior lens zonules and intraocular pressure[J]. Invest Ophthalmol Vis Sci, 2018, 59(5): 2015-2023. doi:10.1167/iovs.17-23705
[36] Tan NE, Tracer N, Terraciano A, et al. Comparison of safety and efficacy between ab interno and ab externo approaches to XEN gel stent placement[J]. Clin Ophthalmol, 2021, 15: 299-305. doi:10.2147/OPTH.S292007
[37] Bell K, de Padua Soares Bezerra B, Mofokeng M, et al. Learning from the past: Mitomycin C use in trabeculectomy and its application in bleb-forming minimally invasive glaucoma surgery[J]. Surv Ophthalmol, 2021, 66(1): 109-123. doi:10.1016/j.survophthal.2020.05.005
[38] Karimi A, Lindfield D, Turnbull A, et al. A multi-centre interventional case series of 259 ab-interno Xen gel implants for glaucoma, with and without combined cataract surgery[J]. Eye(Lond), 2019, 33(3): 469-477. doi:10.1038/s41433-018-0243-8
[39] Smith M, Charles R, Abdel-Hay A, et al. 1-year outcomes of the Xen45 glaucoma implant[J]. Eye(Lond), 2019, 33(5): 761-766. doi:10.1038/s41433-018-0310-1
[40] Tan SZ, Walkden A, Au L. One-year result of XEN45 implant for glaucoma: efficacy, safety, and postoperative management[J]. Eye(Lond), 2018, 32(2): 324-332. doi:10.1038/eye.2017.162
[41] Heidinger A, Schwab C, Lindner E, et al. A retrospective study of 199 Xen45 stent implantations from 2014 to 2016[J]. J Glaucoma, 2019, 28(1): 75-79. doi:10.1097/IJG.0000000000001122
[42] Gabbay IE, Allen F, Morley C, et al. Efficacy and safety data for the XEN45 implant at 2 years: a retrospective analysis[J]. Br J Ophthalmol, 2020, 104(8): 1125-1130. doi:10.1136/bjophthalmol-2019-313870
[43] Gillmann K, Mansouri K. Minimally invasive glaucoma surgery: where is the evidence? [J]. Asia Pac J Ophthalmol(Phila), 2020, 9(3): 203-214. doi:10.1097/APO.0000000000000294
[44] Laroche D, Nkrumah G, Ng C. Real-world retrospective consecutive study of ab interno XEN 45 gel stent implant with mitomycin C in black and Afro-Latino patients with glaucoma: 40% required secondary glaucoma surgery at 1 year[J]. Middle East Afr J Ophthalmol, 2020, 26(4): 229-234. doi:10.4103/meajo.MEAJO_126_19
[45] Eraslan M, Özcan AA, Dericioglu V, et al. Multicenter case series of standalone XEN implant vs. combination with phacoemulsification in Turkish patients[J]. Int Ophthalmol, 2021, 41(10): 3371-3379. doi:10.1007/s10792-021-01899-7
[46] Broadway DC, Chang LP. Trabeculectomy, risk factors for failure and the preoperative state of the conjunctiva[J]. J Glaucoma, 2001, 10(3): 237-249. doi:10.1097/00061198-200106000-00017
[47] Oddone F, Roberti G, Posarelli C, et al. Endothelial cell density after XEN implant surgery: short-term data from the Italian XEN glaucoma treatment registry(XEN-GTR)[J]. J Glaucoma, 2021, 30(7): 559-565. doi:10.1097/IJG.0000000000001840
[48] Lenzhofer M, Kersten-Gomez I, Sheybani A, et al. Four-year results of a minimally invasive transscleral glaucoma gel stent implantation in a prospective multi-centre study[J]. Clin Exp Ophthalmol, 2019, 47(5): 581-587. doi:10.1111/ceo.13463
[49] Kerr NM, Lim S, Simos M, et al. Primary needling of the ab interno gelatin microstent reduces postoperative needling and follow-up requirements[J]. Ophthalmol Glaucoma, 2021, 4(6): 581-588. doi:10.1016/j.ogla.2021.02.004
[50] Widder RA, Rennings C, Rössler GF. Open conjunctival revision after XEN45 gel stent implantation as a standardized procedure: a step by step guide. Video article[J]. Ophthalmologe, 2020, 117(8): 806-810. doi:10.1007/s00347-020-01127-0
[51] Seo JH, Lim SH. Recanalization of XEN-45 gel stent occlusion with cortical material after phaco-XEN surgery using Nd: YAG laser treatment: a case report[J]. Medicine(Baltimore), 2021, 100(34): e27010. doi:10.1097/MD.0000000000027010
[52] Ventura-Abreu N, Dotti-Boada M, Muniesa-Royo MJ, et al. XEN45 real-life evaluation: survival analysis with bleb needling and major revision outcomes[J]. Eur J Ophthalmol, 2021: 11206721211012847. doi:10.1177/11206721211012847
[53] Luebke J, Boehringer D, Anton A, et al. Trends in surgical glaucoma treatment in Germany between 2006 and 2018[J]. Clin Epidemiol, 2021, 13: 581-592. doi:10.2147/CLEP.S310542
[1] SHI Boying, LIANG Hao, LI Yihong, TANG Dongyong. Surgical treatment of a cataract complicated by anti-glaucoma surgery in an adult patient with Blau syndrome [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(6): 60-65.
[2] LIU Lele, KONG XiangyunOverview,SHEN JiaquanGuidance. Progress of cyclodestructive surgeries for treating glaucoma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(6): 123-128.
[3] TANG Feiran, KONG XiangyunOverview,SHEN JiaquanGuidance. Research progress in the role of OCTA in measuring superficial peripapillary vessel density in the diagnosis and treatment of glaucoma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(5): 77-82.
[4] ZHAO Ying, ZHANG ShanOverview,XU Jiajun, ZHAO JingruGuidance. Research progress on the protective mechanism of heat shock protein 72 in glaucoma retinal ganglion cells [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2022, 36(5): 83-87.
[5] ObjectiveTo discuss the causes and appropriate treatment for iris neovascularization following the analysis of cases( eyes). MethodsIt was a retrospective case series study involving patients( eyes)with iris neovascularization diagnosed between September and July . All the patients underwent ophthalmic examination, and all the examination findings and treatments were recorded. The causes, correlative factors, and treatment outcomes of iris neovascularization were analyzed. ResultsOf the patients, ( eyes, .%)had retinal ischemic signs, including vitreous hemorrhage and retinal vascularization on fundus fluorescein angiography, ( eyes, .%)did not have retinal ischemic signs. After months of treatment, retinal vascularization resolved in all the cases, and iris neovascularization resolved completely in patients( eyes, .%), iris neovascularization was still found in patients( eyes, .%). ConclusionsAnterior segment ischemia may also lead to iris vascularization, although retinal ischemia was the main cause. Additionally, iris neovascularization may not always resolve with treatment for retinal ischemia. Finally, anti-VEGF drug injection was an effective treatment for iris neovascularization.. Case analysis of 25 cases of iris neovascularizationLI Xuan1,2, HUANG Yingxiang2 1. Department of Ophthalmology, Beijing Friendship Hospital, Capital Medical University, Beijing 100050, China; 2. Department of Fundus Disease and Eye Trauma, Eye Hospital China Academy of Chinese Medicine Sciences, Beijing 100040, ChinaAbstract: [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2020, 34(4): 41-47.
[6] ObjectiveTo discuss the early diagnosis and multidisciplinary diagnosis and treatment of neovascular glaucoma in ocular ischemic syndrome. MethodsThe medical records of a 54-year-old male patient with cerebral infarction who presented with right-eye vision loss that had persisted for a week were reviewed. After slit-lamp examination and fluorescence angiography, he was diagnosed with ocular ischemic syndrome(OIS)complicated by neovascular glaucoma in the right eye and treated with intravitreal injection of anti-VEGF drugs and panretinal photocoagulation. ResultsAfter three months of treatment, the right-eye iris neovascularization subsided, and the intraocular pressure was controlled within normal limits. ConclusionOcular ischemia is often missed or misdiagnosed by ophthalmologists, neurologists, cardiologists, and vascular surgeons due to its insidious onset and complex clinical manifestations. Therefore, the establishment of multidisciplinary diagnosis and treatment can improve the prognosis of OIS patients.. Neovascular glaucoma in ocular ischemic syndrome: a case report and literature reviewQIN Shuqi1, WANG Luping1, JIANG Bin2, WANG Yanling1 1. Department of Ophthalmology, Beijing Friendship Hospital, Capital Medical University, Beijing 10050, China; 2. Department of Neurology, Beijing Friendship Hospital, Capital Medical University, Beijing 10050, ChinaAbstract: [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2020, 34(4): 53-55.
[7] Ruibao LIU,Ying ZHAO,Minglu GUO,Yu DUAN,Yanxia WU,Xuejing LU. Autophagy and its research progress in glaucoma [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2019, 33(5): 158-161.
[8] LIU Lin, ZHENG Hua, CHEN Shaolin, DUAN Xuanchu. Neuroprotective effects and safety of stem cell transplantation in rats with experimental glaucoma: a systematic review [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2019, 33(4): 138-144.
[9] TENG Xingbo, CAO Zhi, SUN Haixia, LIU Xianjin, YANGa Weizhou, ZHU Yan, ZHU Yuguang. Role of GRP94 and EIF2α in trabecular bone of primary angle-closure glaucoma patients [J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2019, 33(2): 115-118.
[10] XIE Hongbin, YANG Meina, CHEN Qingshan, LIU Xuyang, FAN Ning. Analysis of immunoglobulin G4-related ophthalmic disease associated with secondary glaucoma [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2018, 32(2): 99-102.
[11] GAO Xue, HAO Linlin, LIU Shaohua, ZHANG Han. Comparison of two intraocular lens measurement formulas for prediction of postoperative refraction accuracy in patients with angle closure glaucoma and cataract [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2018, 32(1): 68-71.
[12] XU Xiao. Clinical observations of Ex-PRESS glaucoma filtration device implantation in patients with glaucoma. [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2017, 31(4): 90-93.
[13] . Efficacy and safety of EX-PRESS implanation versus trabeculectomy for open-angle glaucoma: a meta-analysis. [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2017, 31(2): 104-111.
[14] . The aqueous levels of TNF-α and IP-10 in different kinds of glaucoma and their correlation. [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2017, 31(1): 103-106.
[15] YANG Hongling. Research advances on the assessment and influencing factors of glaucoma patients’ quality of life. [J]. JOURNAL OF SHANDONG UNIVERSITY (OTOLARYNGOLOGY AND OPHTHALMOLOGY), 2016, 30(6): 94-97.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Website Copyright: Editorial Office of Journal of Otolaryngology and Ophthalmology of Shandong University
Address: No.27 Shanda South Road, Jinan, Shandong, China. Post code: 250100 Tel: +86-0531-88366912 Email: ebhxb@sdu.edu.cn Supported by Beijing Magtech Co.Ltd